Summary & Overview
HCPCS J2260: Injection, Milrinone Lactate, 5 mg
HCPCS Level II code J2260 denotes a 5 mg injection of milrinone lactate, an intravenous inotropic agent used for short-term management of acute decompensated heart failure and other conditions requiring inotropic support. Nationally, accurate coding for parenteral inotropes matters for clinical documentation, drug utilization tracking, payer adjudication, and hospital billing for acute cardiac care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise information on clinical context, typical sites of service, common modifiers, and payer coverage patterns where available. The publication highlights benchmark considerations, billing nuances for unitization of drug doses, and relevant administrative details that affect claim processing for milrinone lactate.
The report provides operationally focused content: how J2260 maps to parenteral drug administration workflows, implications for inpatient and emergency care billing, and areas where coding accuracy affects reimbursement and utilization review. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2260 describes an injection of milrinone lactate, 5 mg. This code represents a single unit dose of milrinone lactate, a phosphodiesterase-3 inhibitor used for short-term inotropic support in patients with acute decompensated heart failure or related cardiovascular conditions.
Service Type: Drug administration — parenteral medication
Typical Site of Service: Inpatient hospital, emergency department, or other acute care settings where intravenous infusions or bolus injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J2260 (Injection, milrinone lactate, 5 mg) is an adult hospitalized for acute decompensated heart failure with evidence of low cardiac output and persistent hypotension despite volume optimization and standard intravenous vasodilator/diuretic therapy. The patient is usually managed in an inpatient acute care setting such as a medical intensive care unit or monitored step-down unit where continuous hemodynamic monitoring (telemetry, arterial line, or pulmonary artery catheter) is available.
A common clinical workflow: the cardiology or critical care team documents the indication (for example, short-term inotropic support for cardiogenic shock or low-output heart failure). Pharmacy compounds the milrinone infusion or prepares bolus doses per institutional protocol. Nursing administers the medication intravenously as either a loading bolus followed by continuous infusion or infusion alone, with frequent monitoring of blood pressure, heart rate, urine output, and signs of arrhythmia. Dose adjustments are made by the ordering clinician based on hemodynamic response and renal function. Documentation includes the medication name and HCPCS code J2260, dose in milligrams received, route of administration, time and date, indication, and any relevant monitoring data or adverse reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |